Rapid-VIDITEST SARS-CoV-2 (RBD) IgG

Rapid-VIDITEST anti-SARS-CoV-2 (RBD) IgG is a rapid chromatographic immunoassay for the qualitative detection of IgG antibodies against the receptor binding domain (RBD) of SARS-CoV-2 spike protein (S1) in human whole blood, serum and plasma samples.

It is intended for use as an aid in the identification of individuals with an adaptive immune response to SARS-CoV-2.

It makes it possible to monitor the antibody response after infection and / or vaccination, ie. helps detect protective and neutralizing antibodies.

The result is ready to be read in 10 minutes (the time span for reading the result is set at 20 minutes) Rapid-VIDITEST anti-SARS-CoV-2 (RBD) IgG was compared to a commercial ELISA assay.

Based on the study, the sensitivity was found to be: 96.8% / specificity: 98.7%.